Search results for " diabetes"

showing 10 items of 2906 documents

Recommendations for clinical monitoring of patients with acid sphingomyelinase deficiency (ASMD)

2018

Abstract Background Acid sphingomyelinase deficiency (ASMD), a rare lysosomal storage disease, results from mutations in SMPD1, the gene encoding acid sphingomyelinase (ASM). As a result, sphingomyelin accumulates in multiple organs including spleen, liver, lung, bone marrow, lymph nodes, and in the most severe form, in the CNS and peripheral nerves. Clinical manifestations range from rapidly progressive and fatal infantile neurovisceral disease, to less rapidly progressing chronic neurovisceral and visceral forms that are associated with significant morbidity and shorter life span due to respiratory or liver disease. Objectives To provide a contemporary guide of clinical assessments for di…

0301 basic medicinemedicine.medical_specialtyEndocrinology Diabetes and MetabolismDisease030105 genetics & heredityBiochemistryArticle03 medical and health sciencesLiver disease0302 clinical medicineEndocrinologyQuality of lifeInternal medicineGeneticsmedicineLysosomal storage diseaseHumansEnzyme Replacement TherapyMolecular BiologyMonitoring PhysiologicPatient monitoringClinical Trials as TopicAcid sphingomyelinase deficiencyASMDLungbusiness.industryDisease ManagementEnzyme replacement therapyNiemann-Pick Disease Type Amedicine.diseasePhenotypemedicine.anatomical_structureMutationPractice Guidelines as TopicQuality of LifeBone marrowAcid sphingomyelinasebusinessRisk Reduction Behavior030217 neurology & neurosurgerymedicine.drugMolecular Genetics and Metabolism
researchProduct

The efficacy and safety of dipeptidyl peptidase-4 inhibitors compared to other oral glucose-lowering medications in the treatment of type 2 diabetes

2020

ABSTRACT Introduction The dipeptidyl peptidase-4 inhibitors (DPP-4is), which belong to the class of incretin-based medications, are recommended as second or third-line therapies in guidelines for the management of type 2 diabetes mellitus. They have a favorable drug tolerability and safety profile compared to other glucose-lowering agents. Objective This review discusses data concerning the use of DPP-4is and their cardiovascular profile, and gives an updated comparison with the other oral glucose-lowering medications with regards to safety and efficacy. Currently available original studies, abstracts, reviews articles, systematic reviews and meta-analyses were included in the review. Discu…

0301 basic medicinemedicine.medical_specialtyEndocrinology Diabetes and MetabolismIncretin030209 endocrinology & metabolismType 2 diabetesSaxagliptinLinagliptinIncretins03 medical and health scienceschemistry.chemical_compound0302 clinical medicineEndocrinologyInternal medicinemedicineHumansHypoglycemic AgentsVildagliptinDipeptidyl-Peptidase IV InhibitorsPancreatitiHypoglycemic Agentbusiness.industryPancreatic NeoplasmIncretinmedicine.diseasePancreatic NeoplasmsTreatment Outcome030104 developmental biologyDiabetes Mellitus Type 2PancreatitischemistryTolerabilitySitagliptinDipeptidyl-Peptidase IV InhibitorbusinessAlogliptinHumanmedicine.drugMetabolism
researchProduct

Serum metabolites in non-alcoholic fatty-liver disease development or reversion; a targeted metabolomic approach within the PREDIMED trial

2017

Background Limited prospective studies have examined changes in non-alcoholic fatty-liver disease (NAFLD) related serum-metabolites and none the effects of NAFLD-reversion. We aimed to evaluate whether perturbations in metabolites indicate predisposition to NAFLD development and to assess the effects of NAFLD reversion on metabolite profiles. Methods A targeted liquid-chromatography tandem mass-spectrometry metabolic profiling (n = 453 metabolites) approach was applied, using serum from 45 subjects of the PREDIMED study, at baseline and after a median 3.8-year follow-up. NAFLD was determined using the hepatic steatosis index; with three groups classified and studied: Group 1, not characteri…

0301 basic medicinemedicine.medical_specialtyEndocrinology Diabetes and MetabolismMetaboliteMedicine (miscellaneous)lcsh:TX341-641Clinical nutritionBiology03 medical and health scienceschemistry.chemical_compoundFetge--MalaltiesInternal medicineLipid biosynthesisHepatic lipotoxicitymedicineMetabolomicsProspective cohort studylcsh:RC620-627Nutrition and DieteticsFatty acid metabolismResearchFatty livernutritional and metabolic diseasesmedicine.diseasedigestive system diseaseslcsh:Nutritional diseases. Deficiency diseases030104 developmental biologyEndocrinologychemistryLipotoxicityFatty acid metabolismSteatosislcsh:Nutrition. Foods and food supplyNon-alcoholic fatty liver diseaseNutrition & Metabolism
researchProduct

Glycometabolic Alterations in Secondary Adrenal Insufficiency: Does Replacement Therapy Play a Role?

2018

Secondary adrenal insufficiency (SAI) is a potentially life-threatening endocrine disorder due to an impairment of corticotropin (ACTH) secretion from any process affecting the hypothalamus or pituitary gland. ACTH deficit can be isolated or associated with other pituitary failures (hypopituitarism). An increased mortality due to cardiovascular, metabolic, and infectious diseases has been described in both primary and secondary adrenal insufficiency. However, few studies have provided compelling evidences on the underlying mechanism in SAI, because of the heterogeneity of the condition. Recently, some studies suggested that inappropriate glucocorticoid (GCs) replacement therapy, as for dose…

0301 basic medicinemedicine.medical_specialtyEndocrinology Diabetes and MetabolismMini Reviewbody mass index; diabetes mellitus; glucocorticoids; impaired glucose tolerance; insulin resistance; metabolic syndrome; secondary adrenal insufficiency; weight gain030209 endocrinology & metabolismbody mass indexHypopituitarismlcsh:Diseases of the endocrine glands. Clinical endocrinologymetabolic syndromeGrowth hormone deficiencyImpaired glucose tolerance03 medical and health sciences0302 clinical medicineInsulin resistanceEndocrinologyInternal medicineDiabetes mellitusinsulin resistanceMedicineEndocrine systemlcsh:RC648-665glucocorticoidsbusiness.industryweight gainmedicine.disease030104 developmental biologyEndocrinologyimpaired glucose tolerancediabetes mellitussecondary adrenal insufficiencyMetabolic syndromebusinessGlucocorticoidmedicine.drug
researchProduct

Neurotransmitters and Behavioral Alterations Induced by Nickel Exposure.

2020

Background:: Nickel ions (Ni2+) are a heavy metal with wide industrial uses. Environmental and occupational exposures to Ni are potential risk factors for brain dysfunction and behavioral and neurological symptoms in humans. Methods: We reviewed the current evidence about neurochemical and behavioral alterations associated with Ni exposure in laboratory animals and humans. Results: Ni2+ exposure can alter (both inhibition and stimulation) dopamine release and inhibit glutamate NMDA receptors. Few reports claim an effect of Ni2+ at the level of GBA and serotonin neurotransmission. At behavioral levels, exposure to Ni2+ in rodents alters motor activity, learning and memory as well as anxiety…

0301 basic medicinemedicine.medical_specialtyEndocrinology Diabetes and MetabolismPopulationStimulationEnvironmental Illness03 medical and health scienceschemistry.chemical_compound0302 clinical medicineNeurochemicalDopamineNickelInternal medicineImmunology and AllergyMedicineAnimalsHumanseducationNeurotransmittereducation.field_of_studyBehaviorNeurotransmitter Agentsbusiness.industryMental DisordersGlutamate receptorEnvironmental Exposure030104 developmental biologyEndocrinologychemistryNMDA receptorSerotoninbusiness030217 neurology & neurosurgerymedicine.drugEndocrine, metabolicimmune disorders drug targets
researchProduct

Protection in a model of liver injury is parallel to energy mobilization capacity under distinct nutritional status

2019

International audience; Objective: Dietary and energetic restrictions are endowed with protection against experimental injuries. However, a drop in cell energetic status under a critical threshold may prevent protection, as previously observed for livers isolated from rat donors undergoing 18-h fasting versus feeding. The aim of this study was to further explore, in the latter model, links between nutritional status, energy availability, and protection through lengthening of rat fasting to 24 h and withdrawal of energy sources from perfusions.Methods: Energy-free perfused ex vivo livers from fed, 18-h-fasted, and 24-h-fasted rats were studied during 135 min for cytolysis (potassium, asparta…

0301 basic medicinemedicine.medical_specialtyEndocrinology Diabetes and Metabolism[SDV]Life Sciences [q-bio]Nutritional Status030209 endocrinology & metabolismCaspase 303 medical and health scienceschemistry.chemical_compound0302 clinical medicineLactate dehydrogenaseInternal medicineAutophagymedicineAnimalsOrgan protection2. Zero hungerLiver injury030109 nutrition & dieteticsNutrition and DieteticsLiver injury modelGlycogenLiver cytolysisAutophagyEnergy mobilizationFastingSciences bio-médicales et agricolesProtective Factorsmedicine.diseaseLC3IIRats[SDV] Life Sciences [q-bio]PerfusionCytolysisDisease Models AnimalEndocrinologychemistryLiverApoptosisChemical and Drug Induced Liver InjuryEnergy sourceEnergy Metabolism
researchProduct

Role of Adipokines and Perivascular Adipose Tissue in Abdominal Aortic Aneurysm: A Systematic Review and Meta-Analysis of Animal and Human Observatio…

2021

Improved understanding of abdominal aortic aneurysms (AAA) pathogenesis is required to identify treatment targets. This systematic review summarized evidence from animal studies and clinical research examining the role of adipokines and perivascular adipose tissue (PVAT) in AAA pathogenesis. Meta-analyses suggested that leptin (Standardized mean difference [SMD]: 0.50 [95% confidence interval (CI): −1.62, 2.61]) and adiponectin (SMD: −3.16 [95% CI: −7.59, 1.28]) upregulation did not significantly affect AAA severity within animal models. There were inconsistent findings and limited studies investigating the effect of resistin-like molecule-beta (RELMβ) and PVAT in animal models of AAA. Clin…

0301 basic medicinemedicine.medical_specialtyEndocrinology Diabetes and Metabolismaortic ruptureAdipose tissueAdipokine030204 cardiovascular system & hematologylcsh:Diseases of the endocrine glands. Clinical endocrinologyGastroenterologyPathogenesis03 medical and health sciencesEndocrinologyabdominal aortic aneurysm0302 clinical medicineAdipokinesInternal medicineAnimalsHumansMedicinelcsh:RC648-665adipokineAdiponectinbusiness.industryLeptinmedicine.diseaseAbdominal aortic aneurysmadipose tissueObservational Studies as Topic030104 developmental biologyResistinSystematic ReviewAnimal studiesperiaortic adipose tissuebusinessAortic Aneurysm AbdominalFrontiers in Endocrinology
researchProduct

Liraglutide Increases Serum Levels of MicroRNA-27b, -130a and -210 in Patients with Type 2 Diabetes Mellitus: A Novel Epigenetic Effect

2020

Liraglutide has shown favourable effects on several cardiometabolic risk factors, beyond glucose control. MicroRNAs (miRNAs) regulate gene expression, resulting in post-transcriptional modifications of cell response and function. Specific miRNAs, including miRNA-27b, miRNA-130a, and miRNA-210, play a role in cardiometabolic disease. We aimed to determine the effect of liraglutide on the serum levels of miRNA-27b, miRNA-130a and miRNA-210. Twenty-five subjects with type-2 diabetes mellitus (T2DM), na&iuml

0301 basic medicinemedicine.medical_specialtyEndocrinology Diabetes and Metabolismlcsh:QR1-502IncretinType 2 diabetestype-2 diabetes030204 cardiovascular system & hematologyBiochemistryArticlelcsh:Microbiologyliraglutide; microRNAs; type-2 diabetes; cardiometabolic risk; epigenetic03 medical and health sciences0302 clinical medicineInterquartile rangeDiabetes mellitusInternal medicinecardiometabolic riskMedicineMolecular Biologyliraglutidebusiness.industryLiraglutideType 2 Diabetes MellitusMicroRNAmedicine.diseaseMetforminmicroRNAs030104 developmental biologyEndocrinologybusinessHomeostasisepigeneticmedicine.drugMetabolites
researchProduct

2016

Context: Roux-en-Y gastric bypass (RYGB) surgery is an effective long-term intervention for weight loss maintenance, reducing appetite, and also food reward, via unclear mechanisms. Objective: To investigate the role of elevated satiety gut hormones after RYGB, we examined food hedonic-reward responses after their acute post-prandial suppression. Design: These were randomized, placebo-controlled, double-blind, crossover experimental medicine studies. Patients: Two groups, more than 5 months after RYGB for obesity (n = 7–11), compared with nonobese controls (n = 10), or patients after gastric banding (BAND) surgery (n = 9) participated in the studies. Intervention: Studies were performed aft…

0301 basic medicinemedicine.medical_specialtyEndocrinology Diabetes and Metabolismmedia_common.quotation_subjectClinical BiochemistryOctreotide030209 endocrinology & metabolismContext (language use)medicine.disease_causeBiochemistrylaw.invention03 medical and health sciences0302 clinical medicineEndocrinologyRandomized controlled triallawWeight lossInternal medicinemedicinemedia_commonGastric bypass surgerybusiness.industrydigestive oral and skin physiologyBiochemistry (medical)nutritional and metabolic diseasesAppetitemedicine.diseaseCrossover studyObesity3. Good health030104 developmental biologyEndocrinologymedicine.symptombusinessmedicine.drugThe Journal of Clinical Endocrinology & Metabolism
researchProduct

Vitamin D across growth hormone (GH) disorders: From GH deficiency to GH excess

2017

The interplay between vitamin D and the growth hormone (GH)/insulin-like growth factor (IGF)-I system is very complex and to date it is not fully understood. GH directly regulates renal 1 alpha-hydroxylase activity, although the action of GH in modulating vitamin D metabolism may also be IGF-I mediated. On the other hand, vitamin D increases circulating IGF-I and the vitamin D deficiency should be normalized before measurement of IGF-I concentrations to obtain reliable and unbiased IGF-I values. Indeed, linear growth after treatment of nutritional vitamin D deficiency seems to be mediated through activation of the GH/IGF-I axis and it suggests an important role of vitamin D as a link betwee…

0301 basic medicinemedicine.medical_specialtyEndocrinology Diabetes and Metabolismmedicine.medical_treatment030209 endocrinology & metabolismGrowth hormonevitamin D deficiencySettore MED/13 - EndocrinologiaGrowth hormone deficiency03 medical and health sciences0302 clinical medicineEndocrinologyInternal medicineAcromegalyVitamin D and neurologyHumansMedicineInsulin-Like Growth Factor IVitamin DGrowth Disordersgrowth hormone vitamin DHuman Growth Hormonebusiness.industryGrowth factormedicine.diseaseGrowth hormone treatment030104 developmental biologyEndocrinologyAcromegalybusinessGH DeficiencyGrowth Hormone & IGF Research
researchProduct